Company intelligence / Profile preview
Promatix Biosciences
London, England, United Kingdompro-matix.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Promatix is developing a pipeline of novel bispecific antibody-drug conjugates, exemplified by preclinical assets in colorectal cancer. The company leverages its TxPro platform to identify new target combinations that improve tumor selectivity and reduce off-tumor toxicity. No clinical results have been published as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodies (including cis-bispecific ADCs)Antibody Drug Conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
ALSA Ventures — seed funding/incubation partner, academic collaborations mentioned but not named specifically.
Beyond the preview
Go deeper on Promatix Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promatix Biosciences.